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Abstract 
ES-62, a glycoprotein secreted by the filarial nematode Acanthocheilonema viteae, 
exhibits anti-inflammatory properties by virtue of covalently attached 
phosphorylcholine (PC) moieties. Screening of a library of ES-62 PC-based small 
molecule analogues (SMAs) revealed that two compounds, termed 11a and 12b, 
mirrored the helminth product both in inhibiting mast cell degranulation and cytokine 
responses in vitro and in preventing ovalbumin-induced Th2-associated airway 
inflammation and eosinophil infiltration of the lungs in mice. Furthermore, the two 
SMAs inhibited neutrophil infiltration of the lungs when administered therapeutically. 
ES-62-SMAs 11a and 12b thus represent starting points for novel drug development 
for allergies such as asthma.  
 
Keywords: Asthma; ES-62; Parasitic helminth; Immunomodulation; 
Phosphorylcholine  
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Asthma is a chronic ailment of the lungs associated with airway inflammation and 
exaggerated responses to infections, allergens and irritants that has shown a clear 
increase in occurrence in Western countries in recent decades. For example, asthma 
incidence rose in the USA from 7.3% in 2001 to 8.4% in 2010 such that the number 
of people afflicted reached 25.7 million, with prevalence highest in children 
(Akinbami et al., 2012). However, such an increase has not been mirrored in rural 
areas of the Third World where parasitic worms are highly abundant (see Keiser and 
Utzinger, 2010) and this has led to the suggestion that such pathogens may protect 
humans from developing asthma. Although the situation is not clear-cut and may be 
influenced by factors such as the species of helminth under study, there is sufficient 
supportive evidence for this idea to possess some merit (reviewed by Cooper, 2009). 
Furthermore, an increasing body of data exists to show that parasitic worms or their 
secreted products can prevent the development of allergic conditions in the lungs in 
mouse models (reviewed by Danilowicz-Luebert et al., 2011). One such secreted 
product, ES-62, a phosphorylcholine (PC)-containing glycoprotein derived from the 
rodent filarial nematode Acanthocheilonema viteae (Harnett et al., 1989), can directly 
interfere with allergic responses by blocking mast cell activation via the high affinity 
IgE receptor, FcεRI, thereby preventing release of inflammatory mediators (Melendez 
et al., 2007; Ball et al., 2013). However, as shown in a mouse model of ovalbumin 
(OVA)-induced airway hyper-reactivity (OAH), it is also able to prevent disease by 
reversing the Th2 cell polarity that contributes to allergy (Melendez et al., 2007; 
Rzepecka et al., 2013). These data suggest that ES-62 could exhibit therapeutic 
potential in human asthma but it is a large and hence potentially immunogenic 
molecule and thus in theory is likely to be unsuitable for use as a drug. For this 
reason, we decided to investigate a recently prepared library of drug-like small 
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molecule analogues (SMAs) of ES-62 (Al-Riyami et al., 2013). These focus on the 
PC moiety of the helminth product, as we have previously shown this to be 
responsible for many of its anti-inflammatory activities (Harnett et al., 2008).   
                We first investigated in vitro mast cell responses. FcεRI-mediated mast cell 
activation (degranulation and cytokine secretion) is dependent on the mobilization of 
intracellular calcium (Gilfillan and Beaven, 2011; Wu, 2011; MacGlashan, 2012) and 
consistent with this, we have previously shown that the ES-62-mediated 
desensitization of such mast cell function is associated with suppression of calcium 
signalling in human bone marrow-derived mast cells (BMMCs) and mouse 
peritoneal-derived mast cells (PDMCs) (Melendez et al., 2007; Ball et al., 2013). We 
therefore employed Fura-2-acetyoxymethyl ester (Fura-2AM) tracking of calcium 
mobilization as a screen for testing the ability of ES-62 SMAs (65 in total) to 
similarly desensitise mouse BMMC responses. Only a small number of the 
compounds showed any evidence of being able to suppress FcεRI-mediated calcium 
mobilization, with the sulfones 11a and 12b (Fig. 1A and B), which reduced 
mobilization to 66.4 ± 3.5% and 62.6 ± 5.5 % (mean ± S.E.M.) of the control value, 
respectively  (Fig. 1A and B), being most effective. These two SMAs were therefore 
selected for further analysis as possible anti-allergy ES-62 mimics; of note, we had 
previously shown one of them - 11a - to prevent development of collagen-induced 
arthritis (CIA) in mice (Al-Riyami et al., 2013).  
Continuing with mast cells, 11a and 12b were first tested for their ability to 
inhibit degranulation of these cells when activated via FcεRI. We have recently 
shown (Ball et al., 2013) that whilst mouse BMMCs produce high levels of 
eicosanoids, cytokines and chemokines, they make poor degranulation responses to 
activation via FcεRI. By contrast, PDMCs respond strongly in terms of degranulation, 
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but not cytokine production, following stimulation with antigen, whilst bone marrow-
derived connective tissue type mast cells (CTMCs) display an intermediate 
phenotype. Importantly, ES-62 was able to desensitize FcεRI-signalling in all of these 
mast cell subsets (Ball et al., 2013). Due to their strong degranulation reaction, 
PDMCs were employed to test the effects of 11a and 12b on this mast cell response, 
mediated via FcεRI ligation and crosslinking, and both were found to be able to 
inhibit it (Fig. 1C and D). Similar results were obtained with the rat basophilic 
leukemia cell line RBL-2H3 (results not shown). 11a and 12b were next tested for 
their ability to mimic ES-62 in inhibiting the TNFα (Fig. 1E and F) and IL-6 (Fig. 1G 
and H) responses of BMMCs activated via FcεRI (Ball et al., 2013). Both SMAs were 
found to inhibit secretion of these cytokines and in a dose-dependent manner.   
ES-62-mediated inhibition of human BMMC responses is associated with 
degradation of protein kinase C alpha (PKCα) (Melendez et al., 2007) and subsequent 
uncoupling of FcεRI from phospholipase D (PLD) and sphingosine kinase (SphK), 
signals that have been shown to be important in calcium mobilization and 
degranulation in mast cells (Gilfillan and Beaven, 2011; Spiegel and Milstien, 2011). 
Similarly, we have shown ES-62-mediated desensitization of mouse PDMC, BMMC 
and CTMC degranulation and/or cytokine release to be associated with PKCα 
degradation (Ball et al., 2013). Thus, to determine whether SMAs 11a and 12b were 
mimicking this mechanism of action of ES-62, we investigated the effect of these 
SMAs on PKCα expression using quantitative laser-scanning cytometry (Harnett, 
2007). PC conjugated to BSA was used as a positive control (and compared with 
BSA) for this experiment due to the ability of PC-conjugates such as this to mimic 
immunomodulation by ES-62 (Harnett et al., 2008; Al-Riyami et al., 2013) and as 
shown in Fig. 2, both SMAs mirrored PC-BSA in down-regulating expression of 
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PKCα in mouse BMMCs. This was evident not only in the percentage of mast cells 
positive for PKCα, but also in a reduction of the levels of PKCα expression (mean 
fluorescence integral; MFI) and in terms of foci of PKCα expression (maximum 
pixel). The last result suggested that the residual low levels of expression observed in 
PC-BSA or SMA-treated cells reflect a dispersed distribution throughout the cells, 
rather than translocation and association in foci with membranes, which would be 
indicative of activation. 
SMAs 11a and 12b were next tested for their ability to mimic ES-62 in an in 
vivo situation, specifically in demonstrating protection against allergic responses in 
the lungs of mice sensitized and challenged with OVA in a prophylactic model 
(Melendez et al., 2007; Rzepecka et al., 2013). This model (Supplementary Fig. S1A) 
gives significant cell infiltration and a strong inflammatory response in the lungs 
during antigen challenge (Patel et al., 2005), and involves targeting of both the 
sensitization and challenge phases by the SMAs. Although we have previously 
reported that ES-62 inhibits mast cell degranulation in the lungs in this model 
(Melendez et al., 2007), the number of mast cells detectable in the bronchoalveolar 
lavage (BAL) is relatively very small and thus we focused on an alternative approach 
to assessing an anti-allergy effect, specifically on measuring the levels of more 
abundant inflammatory cell types that infiltrate the lungs during OVA challenge. 
Thus, as can be seen in Fig 3 the two SMAs successfully reduced eosinophil filtration 
both in terms of the proportion (Fig. 3A) and absolute numbers (Fig. 3B) of cells as 
measured by BAL. Effects on neutrophils were less obvious, e.g., inhibition of 
neutrophil numbers (Fig. 3C) only reached statistical significance with SMA 12b 
employed at a 1 µg dose. No significant effect could be found on either macrophage 
or lymphocyte infiltration via BAL (results not shown). The protective effects of 11a 
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and 12b were confirmed by histological analysis of H & E staining (Fig. 3D and E) 
and were corroborated by findings that, similar to ES-62 (Rzepecka et al., 2013), both 
SMAs reduced the mRNA levels of IL-4 (Fig. 3F) and IL-17 (Fig. 3G) which act to 
drive pathogenic Th2 responses in the lungs (Iwakura et al., 2011; Dias and Banerjee, 
2012). The suppression of IL-17 is perhaps surprising in the context of the observed 
relatively weak inhibitory effect of the two SMAs on neutrophil influx of the lungs, 
given the role played by this cytokine in neutrophil recruitment (Ye et al., 2001), but 
the data may simply indicate that the levels of neutrophils in the lungs are not solely 
dependent on local levels of IL-17. At the same time, its targeting may reflect the 
important role of IL-17 in driving eosinophilic inflammation, including in asthma 
(Iwakura et al., 2011; Dias and Banerjee, 2012).  
Finally, we also employed a therapeutic model (Supplementary Fig. 1B) of 
airway hyper-reactivity (Patel et al., 2005), which is more relevant to the clinical 
situation, e.g., in treating asthma exacerbations. In this OVA-based model, SMAs 11a 
and 12b showed evidence of inhibiting both the proportion (Fig. 3H) and absolute 
numbers (Fig. 3I) of neutrophils, but not eosinophils (results not shown) in the BAL. 
We also measured the levels of IL-4 and IL-17 mRNA in the lungs in this therapeutic 
model but although there was a tendency towards a reduction with respect to IL-4, no 
statistically significant changes were observed with either cytokine when mice were 
exposed to the two SMAs (results not shown). Again, the result obtained with IL-17 is 
more indicative of a correlation between local levels of this cytokine and eosinophil, 
rather than neutrophil, infiltration whilst the lack of a statistically significant 
reduction with regards to IL-4 in this therapeutic model may possibly reflect the Th2 
polarisation existing prior to administration of the SMAs. Nevertheless, a statistically 
significant reduction in mRNA for IL-13 (Fig. 3J), another Th2 cytokine known to 
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play a key role in asthma pathogenesis (Wills-Karp, 2004), was observed when a 10 
µg dose of SMA 11a or 12b was employed. Furthermore, this inversely correlated 
with an increase in mRNA for the Th1-associated cytokine IFNγ (Fig. 3K) therefore 
indicating that the two SMAs were showing some evidence of mimicking ES-62 
(Rzepecka et al., 2013) in reversing the polarity of the Th cell response. 
Several parasitic nematode products, in addition to ES-62, including filarial 
nematode cystatin (Schnoeller et al., 2008) and a MIF homologue from Anisakis 
simplex (Park et al., 2009), have been reported to be active in protecting against 
OVA-induced airway hypersensitivity in mouse models. However as alluded to 
earlier, one potential problem in exploiting such immunomodulators for use in the 
clinic is their potential immunogenicity. In the case of ES-62, the active anti-
inflammatory moiety is a nematode-specific post-translational modification (Harnett 
et al., 2008; Al-Riyami et al., 2013) and therefore this provided an opportunity to 
explore a small molecule mimetic approach. By taking this opportunity, we have now 
provided proof-of-principle that drug-like SMAs of a helminth product with anti-
allergy properties can be designed. Furthermore, we have shown not only that these 
compounds mimic the parent molecule in offering protection in a prophylactic model 
of airway hyperresponsiveness, but that they can also be successfully employed in a 
therapeutic model. This strengthens the idea that ES-62-based SMAs represent a 
starting point in novel drug development for the treatment of asthma. The inhibitory 
effect on neutrophils observed in the therapeutic model is particularly interesting 
given the role played by these cells in chronic, steroid-resistant asthma, which is often 
very difficult to treat and where there is a clear unmet clinical need.  
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Figure Legends 
 
Fig. 1. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory 
helminth product ES-62 inhibit mast cell calcium mobilisation, degranulation and 
cytokine production. (A, B) Structures of 11a and 12b and their effects on high 
affinity IgE receptor (FcεRI)-mediated calcium mobilisation. Measurement of 
calcium mobilisation was undertaken as previously described (Ball et al., 2013). 
Mouse bone marrow-derived mast cells (BMMCs) were sensitised with murine anti-
DNP IgE (0.5 µg/ml) in the presence and absence of SMA 11a or 12b (5 µg/ml) 
overnight at 37oC. Following loading with Fura-2-acetyoxymethyl ester (Fura-2AM), 
the cells were stimulated at the 50 s time-point with DNP (0.5 µg/ml) to induce cross-
linking (XL) of FcεR1 and intracellular calcium mobilisation and influx was then 
recorded in real time using excitation-emission ratios of 340/380 nm. Data are 
presented as the mean calcium values of triplicate samples and ***P < 0.001 by 
ANOVA and Newman-Keuls multiple comparison test. (C, D) PDMCs and (E-H) 
BMMCs were pre-treated with the indicated concentrations of 11a and 12b (1, 2 or 5 
µg/ml) during the IgE sensitisation phase and then degranulation was measured by 
release of β-hexosaminidase as described previously (Melendez et al., 2007; Ball et 
al., 2013) 1 h following crosslinking of the IgE-bound FcεRI (XL) or not (C, D).  (E, 
F) TNFα and (G, H) IL-6 release were measured by ELISA as described previously 
(Melendez et al., 2007; Ball et al., 2013) 24 h following crosslinking. Data are 
presented as means ± S.D. where n = 3 and analysis is by one-way ANOVA and 
Newman-Keuls post test where ***P < 0.001. All data are representative of at least 
three independent experiments. 
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Fig. 2. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory 
helminth product ES-62 induce Protein Kinase C alpha (PKCα) down-regulation in 
mouse bone marrow-derived mast cells (BMMCs). PKCα expression was measured 
by laser scanning cytometry (LSC) as described previously (McGrath et al., 2011). 
BMMCs were sensitised with anti-DNP-IgE overnight in the presence of 1 µg/ml of 
BSA, phosphorylcholine (PC)-BSA, SMA 11a or SMA 12b prior to fixing, 
permeabilising and staining of PKCα expression using anti-mouse PKCα antibody. 
(A) Exemplar plots of the gating strategy for quantitative analysis of BMMCs (gated 
on DAPI staining of their nuclei) for PKCα expression mean fluorescence integral 
(MFI) relative to an IgG2a isotype control. (B) The relocation feature of the LSC 
generates representative images (x40) of PKCα (Alexa 488; green) expression by 
BMMCs from each treatment group, counterstained with DAPI (blue) to identify the 
cell nucleus. Images were captured using a Hamamatsu Orca ER digital camera and 
the OpenLab 3.0.9 digital imaging program (Improvision). (C) Analysis by Wincyte 
software of at least 2000 BMMCs under each treatment condition allowed 
quantitation of the percentage of PKCα+ BMMCs in each group, the MFI value of 
PKCα expression by BMMCs and the maximum (max) pixel value of PKCα 
expression by BMMCs.   
 
Fig. 3. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory 
helminth product ES-62 suppress Ovalbumin (OVA)-induced Airway Hyper-
responsiveness (OAH). BALB/c mice undergoing OAH (OVA) were treated with 
SMAs 11a (1 or 10 µg/dose) or 12b (1 or 10 µg/dose) either prophylactically (s.c.; A-
G) as described in Supplementary Fig. S1A and previously (Rzepecka et al., 2013) or 
therapeutically (intra-nasal; H-K) where mice only received SMAs 1 hour before 
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OVA challenge on days 25, 26 and 27 of the experiment as described in 
Supplementary Fig. S1B. Mice were assessed at sacrifice via bronchoalveolar lavage  
(BAL) for lung eosinophil (A, B) or neutrophil infiltration (C, H, I) and lung 
pathology as indicated by H & E staining from two independent models (D and E; 
PBS represents control mice). In A-C, data are pooled from three independent 
experiments and for H and I, data are pooled from four independent experiments. 
Analysis of IL-4 (F), IL-17 (G) IL-13 (J) and IFNγ (K) mRNA levels in the lungs 
from the various treatment groups from a single prophylactic (F, G) or therapeutic (J, 
K) experiment are shown. Real time quantitative Reverse Transcription (qRT)-PCR 
procedures were carried out as described previously (Rzepecka et al., 2013) and 
according to the manufacturer’s instructions (Applied Biosystems, Carlsbad CA, 
USA) using assay kits, Mm 00445259_m1 (IL-4), Mm00439619_m1 (IL-17), 
Mm00434204_m1 (IL-13), Mm 01168134_ml (IFNγ) and Mm 99999915_g1 
(GAPDH). All samples were examined in triplicate and data analysed by StepOne 
software using the comparative CT (∆∆CT) (Applied Biosystems) with values for 
samples being normalised to the reference reporter GAPDH. All data represent 
responses from individual mice in the indicated groups. Where relevant, analysis was 
by one-way ANOVA using Bonferroni’s post test; *P < 0.05, **P < 0.01 and ***P < 
0.001, respectively. All procedures were conducted in accordance with home office 
UK animal guidelines and with the approval of the local ethical committees.   
 
Supplementary Figure legend 
 
Supplementary Fig. S1. Model of ovalbumin (OVA)-induced airway 
hypersensitivity. Six to 8 week old female BALB/c mice were sensitised by i.p. 
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injection of 100 µg of OVA in 200 µl of 1% alum (Alhydrogel; Brenntag Biosector, 
Fredriksund, Denmark) on days (d) 0 and 14. Subsequently on day 14 mice were 
challenged by the intranasal (i.n.) route with 50 µg of OVA in 30 µl of PBS 
(endotoxin-free, Lonza, Slough, UK) after anaesthesia was induced with isoflurane. 
On days 25, 26 and 27 mice were anaesthetised and re-challenged i.n. with 50 µg of 
OVA in 30 µl of PBS. Control mice received PBS in place of OVA. (A) For the 
prophylactic model, 1 or 10 µg of SMAs 11a or 12b in 100 µl of PBS was 
administered by s.c. injection in the scruff of the neck on days –2, 12, 25 and 27. (B) 
For the therapeutic model, 1 or 10 µg of SMAs 11a or 12b in 30 µl of PBS was 
administered by the i.n. route, 1 hour prior to OVA administration on days 25, 26 and 
27. In both models, mice were subjected to euthanasia on day 28 by lethal i.p. 
injection of avertin (1,1,1-tribromoethanol) dissolved in iso-amyl alcohol and diluted 
1/40, and bronchoalveolar lavage (BAL) and analyses undertaken as described in the 
text.   
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Highlights 
 
• Small molecule analogues of the helminth immunomodulator ES-62 have been 
produced 
 
• Two analogues inhibit mast cell functions and prevent airway hypersensitivity  
 
• The analogues are drug-like and could be considered for treatment of human 
allergy 
 
